ArticleFrontiers in neurology2025
Glucose dysregulation and glycemic phenotyping in chronic migraine.
Article in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Migraine and Obesity: From Shared Mechanisms to Therapeutic Strategies.Neurology and therapy · 2026Review
- Glucose Dysregulation as a Driver of Autoimmune Mimicry, Inflammation, and Psychiatric Symptoms: A Narrative Review.Biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Emerging evidence suggests that a metabolic mismatch between cerebral energy demand and supply may be a contributing factor to the onset of migraine. Studies have drawn connections between migraine and conditions such as hypoglycemia, fasting, GLUT1 transporter deficiency, insulin resistance, and diabetes, highlighting the role of metabolic dysregulation in migraine susceptibility. Understanding these metabolic patterns could pave the way for personalized migraine treatments targeting glucose regulation. Methods: We conducted a retrospective cohort analysis of chronic migraine subjects (>15 headache days/month) using continuous glucose monitoring (CGM; Results: Compared to age- and gender-matched standards of normal GTT response, individuals with chronic migraine had significantly lower glucose values at fasting and 2 h. CGM data further revealed that migraine subjects exhibited greater glucose variability, including increased day-to-day (MODDs) and within-day (CONGA24) glycemic variability, and higher interday and intraday standard deviation during waking hours. Post-prandial dysregulation was also observed in measures of MAGE, MGE, PGRT, and PPAUC, with all metrics except PGRT differing significantly from controls during waking hours. Clustering of glucose tolerance test results identified three distinct phenotypes, each characterized by unique glucose and insulin response profiles. Discussion: Chronic migraine subjects exhibited postprandial glucose dysregulation and greater glycemic variability than healthy controls. The identified GTT phenotypes reveal distinct glucose regulation patterns, suggesting the existence of different migraine-associated metabolic profiles. Future research will investigate factors contributing to these phenotypes and their implications for migraine pathogenesis. These findings support the potential for developing targeted migraine treatments informed by glucose dysregulation patterns.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.